The Economic Value Of An Innovative Knee Implant System For Total Knee Arthroplasty

Abstract

A 1 -A 2 9 8 A225 available on the Mexican Formulary Catalog (naproxen/esomeprazole, NSAIDs group and celecoxib). Incremental cost-effectiveness ratio (ICER) was performed with two measures: Life Years without AE (LY) and Quality Adjusted Life Years (QALYs). The analysis was done from public perspective, only considered direct costs, and is reported in US dollars. RESULTS: Treatment with naproxen/esomeprazole versus NSAIDs represents an ICER of $318.85 for one year without AE; celecoxib had an ICER of $1,226.59, less effective than naproxen/esomeprazole. The ICER per QALY gain was $1,363.26 for naproxen/esomeprazole and $4,562.90 for celecoxib. Sensitivity analysis confirms the consistency of the results. CONCLUSIONS: Naproxen/esomeprazole FDC dominated celecoxib and NSAIDs. The use of naproxen/esomeprazole in the treatment of patients with OA at risk of developing GI AE is cost-effective and could be considered as the first option in an institutional setting.